Hemispherx Ampligen Filing Will Jumpstart NDA Clock
This article was originally published in The Pink Sheet Daily
Executive Summary
Biopharma accelerates evaluation of the Toll-like receptor-3 agonist as an adjuvant for HIV/AIDS and avian influenza vaccines.
You may also be interested in...
Merck, NIH Cannot Explain Higher Number Of AIDS Cases In HIV Vaccinated Individuals
In some instances, the vaccine may have led to an increase in HIV infections.
Hemispherx Submits NDA For First-Ever Chronic Fatigue Syndrome Therapy
Complete Ampligen NDA was submitted to FDA Oct. 10, CEO Carter tells “The Pink Sheet” DAILY.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.